Press Releases Year None2020201920182017 May 14, 2020 Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights May 5, 2020 Prevail Therapeutics to Present at Bank of America Global Research Virtual Health Care Conference 2020 April 29, 2020 Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting March 31, 2020 Prevail Therapeutics to Present at AAT-AD/PD Focus Meeting 2020: Advances in Alzheimer’s and Parkinson’s Therapies March 26, 2020 Prevail Therapeutics Reports Full Year 2019 Financial Results and Business Highlights March 24, 2020 Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR006 to Slow the Progression of Frontotemporal Dementia with a GRN Mutation March 3, 2020 Prevail Therapeutics Provides Clinical Advancement Update on PR001 for the Treatment of Parkinson’s Disease with GBA1 mutations March 2, 2020 Prevail Therapeutics Announces Investigational New Drug Application Active for PR006 for the Treatment of Frontotemporal Dementia with GRN Mutation February 21, 2020 Prevail Therapeutics to Present at Upcoming Conferences February 12, 2020 Prevail Therapeutics’ PR001 Receives Orphan Drug Designation and Rare Pediatric Disease Designation from FDA Pagination First page « first Previous page ‹ previous Page 1 Page 2 Current page 3 Page 4 Next page next › Last page last » Displaying 21 - 30 of 32
